Our study did not include any biological data [i.e., O6–methylguanine DNA methyltransferase (MGMT) promoter methylation status, or isocitrate dehydrogenase (IDH) mutation status], nor the presence of residual tumor after the 6th cycle (e.g., our study did not provide information on the reasons why the temozolomide was continued, such as the persistence (or not) of enhanced lesions on imaging, or the knowledge of the MGMT status). The gene discussed is IDH3A; the disease is neoplasm.